UroGen Pharma Quarterly Income Statement
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
UroGen Pharma revenue and earnings
In the quarter ended Jun 30, 2026, UroGen Pharma generated $72.5 million in revenue, up 199.2% from the same quarter a year earlier. UroGen Pharma reported a net loss of $14.4 million, compared with a loss of $49.9 million a year earlier. Gross margin was 90.9% (up from 85.3%) and operating margin 0.2%.
Summary generated from market data by MetaCap's automated system. Methodology
UroGen Pharma income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.46M | 50.96M | 37.84M | 27.48M | 24.21M | 20.25M | 24.57M | 25.20M | 21.85M | 18.78M | 23.53M | 20.85M |
| Revenue growth (YoY) | +199.22% | +151.60% | +54.03% | +9.04% | +10.83% | +7.84% | +4.40% | +20.87% | +3.35% | +9.24% | +30.06% | +29.54% |
| Cost of Revenue | 6.57M | 4.14M | 3.29M | 3.28M | 3.55M | 2.33M | 2.47M | 2.45M | 2.23M | 1.73M | 2.29M | 2.37M |
| Gross Profit | 65.88M | 46.82M | 34.55M | 24.20M | 20.66M | 17.92M | 22.09M | 22.75M | 19.62M | 17.05M | 21.24M | 18.48M |
| Operating Expenses | 65.77M | 67.08M | 53.66M | 51.59M | 62.11M | 54.84M | 49.75M | 40.30M | 45.46M | 42.79M | 35.85M | 31.98M |
| Research & Development | 17.34M | 15.60M | 14.31M | 14.01M | 18.91M | 19.87M | 14.89M | 11.36M | 15.40M | 15.49M | 11.30M | 10.23M |
| Selling, General & Admin | 48.44M | 51.49M | 39.35M | 37.58M | 43.20M | 34.97M | 34.86M | 28.94M | 30.06M | 27.30M | 24.55M | 21.75M |
| Operating Income | 111.00K | -20.26M | -19.11M | -27.39M | -41.45M | -36.91M | -27.66M | -17.55M | -25.84M | -25.74M | -14.61M | -13.50M |
| Other Income (Expense) | -347.00K | -323.00K | -5.00K | -197.00K | -378.00K | -90.00K | -62.00K | -158.00K | 174.00K | -183.00K | 812.00K | 71.00K |
| Pretax Income | -8.72M | -28.35M | -26.64M | -34.40M | -48.92M | -43.45M | -34.86M | -23.58M | -33.37M | -32.23M | -22.16M | -21.89M |
| Income Tax | 5.63M | -4.77M | -275.00K | -1.05M | 1.01M | 392.00K | 2.65M | 91.00K | 38.00K | 54.00K | 3.85M | -9.00K |
| Net Income | -14.35M | -23.57M | -26.36M | -33.35M | -49.94M | -43.84M | -37.51M | -23.67M | -33.40M | -32.29M | -26.02M | -21.88M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.28 | -0.47 | -0.53 | -0.69 | -1.05 | -0.92 | -0.80 | -0.51 | -0.82 | -0.87 | -0.72 | -0.68 |
| Shares Outstanding (Basic) | 50.38M | 50.18M | — | 48.06M | 47.74M | 47.42M | 47.03M | 46.78M | 40.50M | 37.06M | 36.15M | 32.30M |
| EBITDA | 211.00K | -20.19M | -19.04M | -27.29M | -41.35M | -36.84M | -27.59M | -17.45M | -25.74M | -25.62M | -14.42M | -13.30M |
| Gross Margin | 90.93% | 91.88% | 91.31% | 88.07% | 85.34% | 88.50% | 89.94% | 90.27% | 89.80% | 90.80% | 90.28% | 88.65% |
| Operating Margin | 15.00% | -39.76% | -50.52% | -99.65% | -171.17% | -182.26% | -112.59% | -69.61% | -118.27% | -137.05% | -62.09% | -64.74% |
| Net Margin | -19.81% | -46.26% | -69.68% | -121.34% | -206.24% | -216.47% | -152.71% | -93.93% | -152.89% | -171.91% | -110.57% | -104.93% |
This table shows 12 quarterly periods of UroGen Pharma's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow URGN's reporting calendar. What is a income statement?